Teleflex Incorporated (NYSE: TFX) announced its financial results for the third quarter ending September 30, 2026, highlighting steady revenue growth and a strengthened outlook for the remainder of the fiscal year. The medical technology company reported revenue from continuing operations of $567.8 million, representing a 0.2% increase over the same period last year and a 3.0% rise on a pro forma adjusted constant currency basis.
Earnings Performance and Shareholder Returns
In addition to operational gains, Teleflex has actively returned value to shareholders. Since July 1, 2026, the company has repurchased $350 million in common stock through a combination of open-market transactions and an accelerated share repurchase program.
Full-Year 2026 Outlook
Looking ahead, Teleflex is maintaining its pro forma adjusted constant currency revenue growth guidance range of 3.5% to 4.5%. Reflecting confidence in its current trajectory, the company has raised its full-year 2026 adjusted diluted EPS guidance from continuing operations to a range of $7.50 to $7.75.
